Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

Impact · against what's priced in

The announcement of Vertex's acquisition of Crinetics at $85.00 per share provides a concrete valuation floor, while the accompanying shareholder investigation by Ademi LLP is a standard M&A friction point with minimal impact. Similarly, the investigations into Element Solutions and Iridium are typical of buyout scenarios and unlikely to materially alter their valuations.

CRNX+0.60

No priced-in read yet